Traws Pharma (NASDAQ: TRAW) CEO reports new RSU and stock option awards

Rhea-AI Filing Summary

Traws Pharma, Inc. reported an insider equity award for its Chief Executive Officer and director, Iain Dukes. On 12/12/2025, he acquired 36,943 shares of common stock at a price of $0 through an award of restricted stock units, bringing his directly held common stock holdings to 171,130 shares. These restricted stock units are scheduled to vest 100% on the first anniversary of the grant date and each unit will convert into one share of common stock.

On the same date, Dukes received a stock option covering 147,771 shares of common stock with an exercise price of $2.33 per share, granted at a price of $0. These options vest 100% on 12/12/2026 and expire on 12/12/2035, and he beneficially owns 147,771 stock options following this grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dukes Iain D.

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		36,943(1)	A	$0	171,130	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to purchase)	$2.33	12/12/2025		A		147,771		12/12/2026(2)	12/12/2035	Common Stock	147,771	$0	147,771	D

Explanation of Responses:

1. Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

2. The options vest 100% on the first anniversary of the grant date.

	/s/ Iain Dukes	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider equity awards did Traws Pharma (TRAW) report for its CEO?

Traws Pharma reported that Chief Executive Officer and director Iain Dukes received an award of 36,943 restricted stock units of common stock and a stock option for 147,771 shares of common stock.

How many Traws Pharma (TRAW) common shares does Iain Dukes hold after this transaction?

Following the reported transaction on 12/12/2025, Iain Dukes beneficially owns 171,130 shares of Traws Pharma common stock directly.

What are the key terms of the restricted stock units granted to Traws Pharma CEO Iain Dukes?

The award consists of 36,943 restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into one share of common stock.

What are the exercise price and vesting terms of Iain Dukes’ Traws Pharma stock options?

The stock option covers 147,771 shares of common stock with an exercise price of $2.33 per share. The options vest 100% on 12/12/2026 and expire on 12/12/2035.

Did Iain Dukes pay anything for the Traws Pharma equity awards reported on 12/12/2025?

The filing shows both the 36,943 restricted stock units and the 147,771 stock options were granted at a price of $0 to the reporting person.

How many Traws Pharma stock options does Iain Dukes beneficially own after this grant?

After the reported transaction, Iain Dukes beneficially owns 147,771 stock options of Traws Pharma common stock.